Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Cabaletta Bio is a clinical-stage biotechnology company developing engineered T-cell therapies for B-cell mediated autoimmune diseases. The company's lead candidate, CABA-201, is a fully human CD19-CAR T therapy in Phase 1/2 trials for systemic lupus erythematosus (SLE), myositis, and systemic sclerosis, representing a novel application of CAR-T technology beyond oncology. With no revenue and negative cash flow of approximately $100M annually, the company is entirely dependent on clinical trial outcomes and capital markets access for survival.
Cabaletta operates a binary outcome model typical of clinical-stage biotech: invest capital in R&D to advance CABA-201 through FDA trials, targeting regulatory approval for rare autoimmune diseases with limited treatment options. The company's strategy focuses on B-cell depletion using autologous CAR-T therapy, leveraging manufacturing expertise developed in oncology but applied to chronic autoimmune conditions. Monetization depends entirely on achieving positive Phase 2/3 data demonstrating durable remission in SLE or other indications, followed by FDA approval and commercialization or acquisition by a larger pharmaceutical company. Current burn rate of approximately $100M annually suggests 3-4 quarters of runway based on current ratio of 3.60, making near-term clinical milestones and capital raises critical inflection points.
CABA-201 Phase 1/2 clinical trial data releases for SLE, myositis, and systemic sclerosis - particularly safety profile, B-cell depletion durability, and disease remission rates
FDA regulatory interactions including IND clearances for new indications, Fast Track or Breakthrough Therapy designations
Capital raising announcements (equity offerings, ATM programs) which dilute existing shareholders but extend operational runway
Partnership or licensing deals with major pharmaceutical companies for co-development or commercialization rights
Competitive clinical data from rival CAR-T programs targeting autoimmune diseases (Kyverna, Carisma, Cartesian)
Binary clinical trial risk - single Phase 2/3 failure in CABA-201 could render the company's platform value negligible given concentrated pipeline
Manufacturing complexity and cost of autologous CAR-T therapy may limit commercial viability even with positive efficacy data, particularly for chronic diseases requiring repeat dosing
Regulatory uncertainty as FDA has limited precedent for approving CAR-T therapies in autoimmune diseases versus established oncology applications
Multiple well-funded competitors developing CAR-T and cell therapies for autoimmune diseases, including Kyverna (Phase 2 lupus data expected 2026), potentially establishing first-mover advantage
Alternative B-cell depletion approaches including CD20-targeted biologics (rituximab biosimilars) and BTK inhibitors offer less invasive treatment options
Large pharmaceutical companies (Novartis, BMS, Gilead) with established CAR-T manufacturing and commercialization infrastructure could rapidly enter autoimmune space
Significant cash burn of approximately $100M annually with no revenue creates constant dilution risk and potential for unfavorable financing terms
Current ratio of 3.60 suggests adequate near-term liquidity but likely requires capital raise within 12-18 months absent partnership
Negative ROE of -107% and ROA of -83% reflect ongoing losses typical of clinical-stage biotech but limit access to non-dilutive financing
low - Clinical trial timelines and FDA regulatory processes are largely insulated from GDP fluctuations. However, severe recessions can impact patient enrollment if healthcare access deteriorates and may delay partnership negotiations as larger pharma companies conserve capital.
Rising interest rates negatively impact valuation through higher discount rates applied to distant future cash flows (8-10 years to potential commercialization). Higher rates also increase opportunity cost of capital for speculative biotech investments, driving rotation away from pre-revenue growth stocks. Financing costs for debt are minimal given low leverage (D/E 0.18), but equity capital becomes more expensive as risk-free rates rise.
Minimal direct credit exposure. The company relies on equity markets rather than debt financing. However, tightening credit conditions reduce risk appetite among institutional investors, making equity raises more dilutive and potentially forcing unfavorable partnership terms.
growth - Attracts speculative biotech investors seeking asymmetric returns from binary clinical catalysts. The 71% one-year return and 87% six-month return reflect momentum trading around clinical milestones. Institutional ownership likely includes specialized healthcare hedge funds and venture capital rather than broad index funds. Not suitable for value or income investors given pre-revenue status and high volatility.
high - Clinical-stage biotech with $300M market cap exhibits extreme volatility around data releases and financing events. Single-asset risk concentrated in CABA-201 amplifies stock swings. Recent 24% three-month gain suggests elevated beta well above 2.0 relative to broader market.
